CL2010000575A1 - Uso de alfa-1 antitripsina o sus derivados para el tratamiento del sindrome de fatiga cronica, donde dicha antitripsina es purificada del plasma humano o es producida por tecnologia transgenica o recombinante. - Google Patents
Uso de alfa-1 antitripsina o sus derivados para el tratamiento del sindrome de fatiga cronica, donde dicha antitripsina es purificada del plasma humano o es producida por tecnologia transgenica o recombinante.Info
- Publication number
- CL2010000575A1 CL2010000575A1 CL2010000575A CL2010000575A CL2010000575A1 CL 2010000575 A1 CL2010000575 A1 CL 2010000575A1 CL 2010000575 A CL2010000575 A CL 2010000575A CL 2010000575 A CL2010000575 A CL 2010000575A CL 2010000575 A1 CL2010000575 A1 CL 2010000575A1
- Authority
- CL
- Chile
- Prior art keywords
- antitrypsin
- treatment
- transgenic
- alpha
- purified
- Prior art date
Links
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title abstract 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title abstract 2
- 101710081722 Antitrypsin Proteins 0.000 title 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title 1
- 230000001475 anti-trypsic effect Effects 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 title 1
- 239000002753 trypsin inhibitor Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200930387A ES2332645B1 (es) | 2009-06-30 | 2009-06-30 | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2010000575A1 true CL2010000575A1 (es) | 2011-10-28 |
Family
ID=41571181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010000575A CL2010000575A1 (es) | 2009-06-30 | 2010-06-02 | Uso de alfa-1 antitripsina o sus derivados para el tratamiento del sindrome de fatiga cronica, donde dicha antitripsina es purificada del plasma humano o es producida por tecnologia transgenica o recombinante. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205134B2 (enExample) |
| EP (1) | EP2289540B1 (enExample) |
| JP (1) | JP5231490B2 (enExample) |
| CN (1) | CN101934071B (enExample) |
| AR (1) | AR077123A1 (enExample) |
| AU (1) | AU2010202203B2 (enExample) |
| BR (1) | BRPI1002087B1 (enExample) |
| CA (1) | CA2706212C (enExample) |
| CL (1) | CL2010000575A1 (enExample) |
| ES (2) | ES2332645B1 (enExample) |
| MX (1) | MX2010006125A (enExample) |
| NZ (1) | NZ585890A (enExample) |
| PL (1) | PL2289540T3 (enExample) |
| PT (1) | PT2289540E (enExample) |
| RU (1) | RU2436590C1 (enExample) |
| UY (1) | UY32670A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013096458A1 (en) * | 2011-12-19 | 2013-06-27 | Gtc Biotherapeutics, Inc. | Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders |
| WO2014140927A2 (en) | 2013-02-13 | 2014-09-18 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US20220160847A1 (en) * | 2020-11-20 | 2022-05-26 | Mark Egly | Method of preventing and/or treating a plurality of diseases |
| WO2023184473A1 (zh) * | 2022-04-01 | 2023-10-05 | 首创生物技术有限公司 | 肽用于治疗神经退行性疾病或改善认知功能的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2281222A (en) * | 1941-09-27 | 1942-04-28 | American Bosch Corp | Speed regulator for internal combustion engines |
| US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| DK0584185T3 (da) * | 1991-05-14 | 2000-02-07 | Ernir Snorrason | Behandling af træthedssyndrom med cholinesteraseinhibitorer |
| WO2000051623A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| CN1554341A (zh) * | 2000-04-21 | 2004-12-15 | �������Ŷ���Լ��������˾ | 用于治疗纤维肌痛和慢性疲劳综合症的化合物 |
| US20040043510A1 (en) * | 2000-07-14 | 2004-03-04 | Nobuyuki Shigetoh | Particle-labeled protein and immuno-chromatograph using the same |
| CA2506839A1 (en) | 2002-11-20 | 2004-06-03 | Arriva-Prometic Inc. | Composition and method for treating inflammatory diseases using protease inhibitors |
| US7344882B2 (en) * | 2003-05-12 | 2008-03-18 | Bristol-Myers Squibb Company | Polynucleotides encoding variants of the TRP channel family member, LTRPC3 |
| PL2520654T3 (pl) * | 2003-08-26 | 2017-08-31 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych |
| WO2006026837A1 (en) * | 2004-09-07 | 2006-03-16 | Patrick Englebienne | Diagnostic methods for measuring elastase activity levels |
| ES2281222B1 (es) * | 2004-09-24 | 2008-06-01 | Grifols, S.A. | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. |
| EP2114141A2 (en) * | 2007-01-10 | 2009-11-11 | University of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| EP2203051A4 (en) * | 2007-09-25 | 2011-09-07 | Abbott Lab | OCTAHYDROPENTAL COMPOUNDS AS CHEMOKIN RECEPTOR ANTAGONISTS |
| CA2703393C (en) | 2007-11-02 | 2018-07-24 | Talecris Biotherapeutics, Inc. | Method, composition, and article of manufacture for providing alpha-1 antitrypsin |
-
2009
- 2009-06-30 ES ES200930387A patent/ES2332645B1/es not_active Expired - Fee Related
-
2010
- 2010-05-20 ES ES10380071T patent/ES2392691T3/es active Active
- 2010-05-20 PT PT103800710T patent/PT2289540E/pt unknown
- 2010-05-20 PL PL10380071T patent/PL2289540T3/pl unknown
- 2010-05-20 EP EP10380071A patent/EP2289540B1/en active Active
- 2010-05-27 UY UY0001032670A patent/UY32670A/es not_active Application Discontinuation
- 2010-05-28 AU AU2010202203A patent/AU2010202203B2/en active Active
- 2010-06-02 NZ NZ585890A patent/NZ585890A/en not_active IP Right Cessation
- 2010-06-02 CL CL2010000575A patent/CL2010000575A1/es unknown
- 2010-06-03 MX MX2010006125A patent/MX2010006125A/es active IP Right Grant
- 2010-06-04 CA CA2706212A patent/CA2706212C/en active Active
- 2010-06-17 AR ARP100102142A patent/AR077123A1/es unknown
- 2010-06-24 BR BRPI1002087-0A patent/BRPI1002087B1/pt not_active IP Right Cessation
- 2010-06-24 US US12/822,764 patent/US9205134B2/en active Active
- 2010-06-29 JP JP2010147994A patent/JP5231490B2/ja active Active
- 2010-06-29 RU RU2010126653/15A patent/RU2436590C1/ru active
- 2010-06-30 CN CN2010102168418A patent/CN101934071B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1002087B1 (pt) | 2019-07-02 |
| PT2289540E (pt) | 2012-12-04 |
| NZ585890A (en) | 2011-11-25 |
| BRPI1002087A2 (pt) | 2012-03-13 |
| EP2289540B1 (en) | 2012-08-22 |
| US20100331261A1 (en) | 2010-12-30 |
| MX2010006125A (es) | 2011-01-05 |
| HK1148198A1 (en) | 2011-09-02 |
| JP2011012060A (ja) | 2011-01-20 |
| UY32670A (es) | 2011-01-31 |
| ES2332645B1 (es) | 2010-10-18 |
| AU2010202203B2 (en) | 2012-08-23 |
| RU2436590C1 (ru) | 2011-12-20 |
| ES2332645A1 (es) | 2010-02-09 |
| CA2706212C (en) | 2014-02-04 |
| PL2289540T3 (pl) | 2013-03-29 |
| CN101934071A (zh) | 2011-01-05 |
| ES2392691T3 (es) | 2012-12-12 |
| AU2010202203A1 (en) | 2011-01-20 |
| CN101934071B (zh) | 2012-11-28 |
| JP5231490B2 (ja) | 2013-07-10 |
| EP2289540A1 (en) | 2011-03-02 |
| CA2706212A1 (en) | 2010-12-30 |
| AR077123A1 (es) | 2011-08-03 |
| US9205134B2 (en) | 2015-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8784001A1 (es) | Oxazolidinonas sustituidas y su uso | |
| CL2015001241A1 (es) | Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) | |
| CL2011002787A1 (es) | Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica. | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| CL2014000311A1 (es) | Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio. | |
| DOP2014000043A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
| ECSP088358A (es) | Tratamiento y profilaxis de microangiopatías | |
| CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
| SV2010003581A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
| CO6751268A2 (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
| CR20110509A (es) | Composicion farmaceutica | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| MX2013012053A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| CO6640253A2 (es) | Derivados de compuesto biciclico y su uso como inhibidores de acc | |
| BR112012021334A2 (pt) | material biodegradável, contendo silício, para terapia anti-inflamatória. | |
| CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
| CR20110552A (es) | Tratamiento de transtornos resistentes a la insulina | |
| UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
| ECSP11011101A (es) | Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento | |
| CL2009000876A1 (es) | Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno. | |
| CL2010000575A1 (es) | Uso de alfa-1 antitripsina o sus derivados para el tratamiento del sindrome de fatiga cronica, donde dicha antitripsina es purificada del plasma humano o es producida por tecnologia transgenica o recombinante. |